Health state utilities for beta-thalassemia: a time trade-off study.
Antony Paul MartinEnrico Ferri GrazziClaudia MighiuManoj ChevliFarrukh ShahLouise MaherAnum ShaikhAliah SagarHayley HubbersteyBethany FranksJuan M Ramos-GoñiMark OppeDerek TangPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2022)
This study provides health utilities for a range of BT health states from the UK general population perspective. Importantly, lower transfusion burden and lower burden of anemia were associated with higher utilities. To a lesser extent, differential modes of ICT were found to impact utility valuations in patients with BT. The utilities obtained in this study can be employed as inputs in cost-effectiveness analyses of BT therapies.